402 related articles for article (PubMed ID: 24615779)
21. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
22. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
Ngu HS; Savage KJ
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of patients with peripheral T-cell lymphoma treated with first-line intensive chemotherapy followed by autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Papajik T; Vondrakova J; Rusinakova Z; Kucerova L; Myslivecek M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2011 Mar; 155(1):63-9. PubMed ID: 21475380
[TBL] [Abstract][Full Text] [Related]
25. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
26. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.
Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712
[TBL] [Abstract][Full Text] [Related]
27. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
28. Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Kim SJ; Yoon DH; Kang HJ; Kim JS; Park SK; Kim HJ; Lee J; Ryoo BY; Ko YH; Huh J; Yang WI; Kim HK; Min SK; Lee SS; Do IG; Suh C; Kim WS;
Eur J Cancer; 2012 Nov; 48(17):3223-31. PubMed ID: 22770877
[TBL] [Abstract][Full Text] [Related]
29. Update: peripheral T-cell lymphomas.
Savage KJ
Curr Hematol Malig Rep; 2011 Dec; 6(4):222-30. PubMed ID: 21953415
[TBL] [Abstract][Full Text] [Related]
30. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
31. The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients.
Chen H; Tao Y; Zhou Y; Liu P; Yang J; He X; Zhou S; Qin Y; Song Y; Gui L; Zhang C; Yang S; Shi Y
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e202-e214. PubMed ID: 35821612
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
34. Management of Peripheral T-cell Lymphomas and the Role of Transplant.
Foley NC; Mehta-Shah N
Curr Oncol Rep; 2022 Nov; 24(11):1489-1499. PubMed ID: 35947286
[TBL] [Abstract][Full Text] [Related]
35. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
36. Peripheral T-cell lymphoma: a case-based discussion of recent advances in patient management.
Franco CM; Popplewell LL; Horwitz SM
Clin Adv Hematol Oncol; 2011 Apr; 9(4 Suppl 9):1-16. PubMed ID: 21559001
[TBL] [Abstract][Full Text] [Related]
37. Stem cell transplantation for peripheral T-cell lymphomas.
Jantunen E; D'Amore F
Leuk Lymphoma; 2004 Mar; 45(3):441-6. PubMed ID: 15160904
[TBL] [Abstract][Full Text] [Related]
38. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
[TBL] [Abstract][Full Text] [Related]
40. Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Review of Current Disease Understanding and Therapeutic Approaches.
Al-Zahrani M; Savage KJ
Hematol Oncol Clin North Am; 2017 Apr; 31(2):189-207. PubMed ID: 28340873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
